Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 570

1.

The ypT category does not impact overall survival in node negative gastric cancer.

Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD.

J Surg Oncol. 2018 Jun 27. doi: 10.1002/jso.25081. [Epub ahead of print]

PMID:
29949666
2.

Potentially curable gastric adenocarcinoma treated without surgery.

Mizrak Kaya D, Nogueras-Gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A Jr, Devine CE, Das P, Badgwell BD, Ajani JA.

Eur J Cancer. 2018 Jul;98:23-29. doi: 10.1016/j.ejca.2018.04.012. Epub 2018 May 30.

PMID:
29859338
3.

Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma.

Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA.

Oncology. 2018 May 29:1-10. doi: 10.1159/000488489. [Epub ahead of print]

PMID:
29843157
4.

Customization of therapy for gastroesophageal adenocarcinoma patients.

Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA.

Chronic Dis Transl Med. 2018 Mar 13;4(1):8-17. doi: 10.1016/j.cdtm.2018.02.003. eCollection 2018 Mar.

5.

Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved.

Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, Ajani JA, Fournier KF, Mansfield P, Badgwell BD.

Ann Surg Oncol. 2018 Jul;25(7):2012-2017. doi: 10.1245/s10434-018-6471-0. Epub 2018 May 10.

PMID:
29748883
6.

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.

Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G.

Nat Med. 2018 May;24(5):556-562. doi: 10.1038/s41591-018-0012-z. Epub 2018 May 7.

PMID:
29736026
7.

Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching.

Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD.

Gastric Cancer. 2018 May 5. doi: 10.1007/s10120-018-0832-z. [Epub ahead of print]

PMID:
29730720
8.

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ.

Cancer Treat Rev. 2018 May;66:104-113. doi: 10.1016/j.ctrv.2018.04.004. Epub 2018 Apr 22. Review.

9.

Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.

Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS.

Nat Commun. 2018 May 3;9(1):1777. doi: 10.1038/s41467-018-04179-8.

10.

Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort.

Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA.

Oncology. 2018;94(6):345-353. doi: 10.1159/000486720. Epub 2018 Apr 27.

PMID:
29705797
11.

Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma.

Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA.

Ann Transl Med. 2018 Feb;6(4):80. doi: 10.21037/atm.2017.10.28. Review.

12.

Current therapeutic landscape for advanced gastroesophageal cancers.

Lopez A, Harada K, Mizrak Kaya D, Ajani JA.

Ann Transl Med. 2018 Feb;6(4):78. doi: 10.21037/atm.2017.10.29. Review.

13.

Immune checkpoint blockade therapy for esophageal squamous cell carcinoma.

Harada K, Mizrak Kaya D, Baba H, Ajani JA.

J Thorac Dis. 2018 Feb;10(2):699-702. doi: 10.21037/jtd.2018.01.120. No abstract available.

14.

Pyloroplasty may reduce weight loss 1 year after esophagectomy.

Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H.

Dis Esophagus. 2018 Mar 1;31(3). doi: 10.1093/dote/dox127.

PMID:
29579257
15.

Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014.

Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, Ajani JA, Roland CL, Fournier K, Royal R, Mansfield P, Badgwell BD.

Cancer. 2018 Mar 1;124(5):998-1007. doi: 10.1002/cncr.31155. Epub 2018 Feb 2.

16.

Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography.

Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A Jr, Fournier K, Mansfield P, Ajani JA, Badgwell BD.

J Gastrointest Oncol. 2017 Dec;8(6):1009-1017. doi: 10.21037/jgo.2017.04.04.

17.

Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis.

Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):667-676. doi: 10.1016/j.ijrobp.2017.06.2450. Epub 2017 Jun 27.

PMID:
29280461
18.

Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.

Zhao W, Ajani JA, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z, Song S.

Gastroenterology. 2018 Apr;154(5):1524-1537.e6. doi: 10.1053/j.gastro.2017.12.014. Epub 2017 Dec 21.

PMID:
29274868
19.

Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.

Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH.

Radiother Oncol. 2017 Dec 13. pii: S0167-8140(17)32751-2. doi: 10.1016/j.radonc.2017.11.028. [Epub ahead of print]

PMID:
29248170
20.

Medical management of gastric cancer: a 2017 update.

Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A.

Cancer Med. 2018 Jan;7(1):123-133. doi: 10.1002/cam4.1274. Epub 2017 Dec 13. Review.

21.

Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial.

Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Br J Cancer. 2018 Feb 6;118(3):331-337. doi: 10.1038/bjc.2017.423. Epub 2017 Dec 12.

PMID:
29235564
22.

Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency.

Ikoma N, Cloyd J, Badgwell BD, Agnes A, Rodriguez-Bigas M, Ajani JA, You YN.

J Surg Oncol. 2018 Mar;117(4):707-709. doi: 10.1002/jso.24926. Epub 2017 Dec 11.

PMID:
29228462
23.

Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial.

Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Target Oncol. 2018 Feb;13(1):99-106. doi: 10.1007/s11523-017-0540-3.

PMID:
29218623
24.

Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma.

Mizrak Kaya D, Nogueras-González GM, Harada K, Amlashi FG, Roy-Chowdhuri S, Estrella JS, Das P, Lee JH, Weston B, Bhutani MS, Matamoros A Jr, Thomas I, Lin Q, Badgwell BD, Ajani JA.

J Surg Oncol. 2018 Mar;117(4):678-684. doi: 10.1002/jso.24912. Epub 2017 Dec 4.

PMID:
29205363
25.

Liquid biopsies in gastrointestinal malignancies: when is the big day?

Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA.

Expert Rev Anticancer Ther. 2018 Jan;18(1):19-38. doi: 10.1080/14737140.2018.1403320. Epub 2017 Dec 4. Review.

PMID:
29202614
26.

A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma.

Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, Skinner HD, Johnson RL, Ding S, Ajani JA.

Mol Cancer Ther. 2018 Feb;17(2):443-454. doi: 10.1158/1535-7163.MCT-17-0560. Epub 2017 Nov 22.

PMID:
29167315
27.

Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.

Ajani JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S.

Br J Cancer. 2018 Jan;118(1):52-61. doi: 10.1038/bjc.2017.388. Epub 2017 Nov 14.

PMID:
29136404
28.

Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance.

Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA.

Oncotarget. 2017 Jul 13;8(46):81430-81440. doi: 10.18632/oncotarget.19226. eCollection 2017 Oct 6.

29.

Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma.

Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA.

Oncotarget. 2017 May 23;8(45):79356-79365. doi: 10.18632/oncotarget.18119. eCollection 2017 Oct 3.

30.

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS.

Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.

31.

The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging.

In H, Ravetch E, Langdon-Embry M, Palis B, Ajani JA, Hofstetter WL, Kelsen DP, Sano T.

Gastric Cancer. 2018 Jan;21(1):1-9. doi: 10.1007/s10120-017-0765-y. Epub 2017 Sep 25.

PMID:
28948368
32.

A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.

Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G; DIGEST Study Group.

Ann Oncol. 2017 Sep 1;28(9):2142-2148. doi: 10.1093/annonc/mdx275.

PMID:
28911091
33.

Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience.

Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA.

Cancer. 2017 Nov 1;123(21):4106-4113. doi: 10.1002/cncr.30953. Epub 2017 Sep 8.

PMID:
28885712
34.

Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer.

Ikoma N, Blum M, Estrella JS, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD.

J Gastrointest Surg. 2017 Oct;21(10):1563-1570. doi: 10.1007/s11605-017-3539-2. Epub 2017 Aug 17.

PMID:
28819789
35.

Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma.

Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, Sudo K, Onodera H, Suzuki K, Suzuki A, Johnson RL, Wang Z, Song S, Ajani JA.

Gastric Cancer. 2018 Jan;21(1):31-40. doi: 10.1007/s10120-017-0760-3. Epub 2017 Aug 11.

PMID:
28801853
36.

Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project.

Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS.

Clin Cancer Res. 2017 Jul 26. doi: 10.1158/1078-0432.CCR-16-2211. [Epub ahead of print]

PMID:
28747339
37.

Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients.

Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA.

Br J Cancer. 2017 Aug 22;117(5):648-655. doi: 10.1038/bjc.2017.225. Epub 2017 Jul 20.

PMID:
28728163
38.

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.

Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS.

Mol Cancer Ther. 2017 Oct;16(10):2215-2222. doi: 10.1158/1535-7163.MCT-16-0895. Epub 2017 Jul 17.

PMID:
28716815
39.

Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients.

Mizrak Kaya D, Dong X, Nogueras-González GM, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, Ajani JA.

Med Oncol. 2017 Aug;34(8):135. doi: 10.1007/s12032-017-0994-2. Epub 2017 Jul 6.

PMID:
28685276
40.

101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy.

Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A Jr, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA.

Oncology. 2017;93(4):243-248. doi: 10.1159/000475550. Epub 2017 Jul 6.

PMID:
28683449
41.

Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.

Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T, Moehler M.

Clin Cancer Res. 2017 Oct 1;23(19):5671-5678. doi: 10.1158/1078-0432.CCR-17-0025. Epub 2017 Jun 27.

PMID:
28655793
42.

Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy.

Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD.

Gastric Cancer. 2018 Jan;21(1):74-83. doi: 10.1007/s10120-017-0743-4. Epub 2017 Jun 22.

PMID:
28643144
43.

Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.

Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH.

Ann Surg. 2018 Aug;268(2):289-295. doi: 10.1097/SLA.0000000000002352.

PMID:
28628563
44.

Gastric adenocarcinoma.

Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S.

Nat Rev Dis Primers. 2017 Jun 1;3:17036. doi: 10.1038/nrdp.2017.36. Review.

PMID:
28569272
45.

Recent advances in preoperative management of esophageal adenocarcinoma.

Harada K, Mizrak Kaya D, Baba H, Ajani JA.

F1000Res. 2017 Apr 18;6:501. doi: 10.12688/f1000research.10794.1. eCollection 2017. Review.

46.

Current status of ramucirumab in gastroesophageal adenocarcinoma.

Elimova E, Lin Q, Song S, Ajani JA.

Future Oncol. 2017 Aug;13(18):1585-1592. doi: 10.2217/fon-2016-0556. Epub 2017 Apr 24.

PMID:
28436242
47.

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.

Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A.

Ann Oncol. 2017 Sep 1;28(9):2077-2085. doi: 10.1093/annonc/mdx191. Review.

PMID:
28430862
48.

Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma.

Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D.

Oncotarget. 2017 Apr 25;8(17):28696-28710. doi: 10.18632/oncotarget.15645.

49.

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK.

Lancet Oncol. 2017 May;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0. Epub 2017 Mar 23.

PMID:
28343975
50.

Is endoscopic ultrasound examination necessary in the management of esophageal cancer?

DaVee T, Ajani JA, Lee JH.

World J Gastroenterol. 2017 Feb 7;23(5):751-762. doi: 10.3748/wjg.v23.i5.751. Review.

Supplemental Content

Loading ...
Support Center